Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis
Year: 2024
Type: conference-abstract
Source: Blood
Authors: Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Jagan R. Muppidi, Max J Gordon, Yandan Yang, Weihong Xu, Theresa Davies-Hill, Da Wei Huang, Craig J. Thomas, Michele Ceribelli, Frances A Tosto, Anna M Juanitez, Amynah Pradhan, Candis Morrison, Atekelt Tadese, Allison P. Jacob, Heidi Simmons, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H Wilson
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4405042819